ORN News and Press, Orion Group Holdings Inc. Common From 01/29/24

HOUSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced the rebranding of its subsidiary TAS Concrete Construction (“TAS”) as Orion. This move reflects the Company's st...

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced that it will host a virtual KOL ev...

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on January 7 at 3:30 pm PT, at the Marine’s Memorial Club in San Francisco (USA). R...

7th Sachs Annual Neuroscience Innovation Forum 13rd Annual LifeSci Advisors Corporate Access Event Biotech Showcase-2024 42nd Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2024 MADRID, Spain and BOSTON, Jan. 03, 2024 (GLOBE NEWSW...

2024-01-02 23:28:35 ET Summary Orion Group Holdings has achieved a quarterly gross profit of $19.1 million, a 42.5% increase YoY. The company is focusing on improving profitability and has a high backlog of $920 million, exceeding its FY 2022 revenue. Orion Group is divesting ...

2024-01-01 08:00:02 ET Summary In 2023, across two accounts, my portfolios returned +98.4%. In the flagship account, my four-year CAGR (pre-tax), from January 1, 2020 - December 31, 2023, was 46%. This piece discusses what did and didn't work in 2023. What a differen...

2023-12-04 16:40:15 ET Summary The Flagship Account and Smaller Managed Account have performed well year-to-date through November 30, 2023. The blended total return is +71% vs. 4.2% for the Russell 2000. Per Pernas Research, from January 1, 2020 - November 20, 2023, 40.5% of stock...

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous one To extend its cash runway and continue the ongoing clinical trials in CNS and oncology Initial execution of €8 million in two tranches of €4 million ...

Company on track to report top line data milestone in 1Q 2024 A total of 210 participants have been recruited Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEW...